bioRASI
CompanyUnited States
bioRASI develops one asset, in phase 2 (Laromestrocel in aging frailty). Mostly cell therapy acting on inflammation and stem cell maintenance; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
1Allogeneic mesenchymal stem cells repair, regenerate or replace damaged or diseased cells.
Phase 2, Cell therapy, Inflammation, Stem cell maintenance, aging frailty, Alzheimer's disease, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Signals1
- Similar companies6